{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:08:52Z","timestamp":1790770132848,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clml.2023.04.004","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T11:33:50Z","timestamp":1681904030000},"page":"599-605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-1665","authenticated-orcid":false,"given":"Francesco","family":"Gaudio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Dicataldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Di Giovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Cazzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"d'Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommasina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Masciopinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena Emanuela","family":"Laddaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ingravallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.04.004_bib0001","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"issue":"68","key":"10.1016\/j.clml.2023.04.004_bib0002","doi-asserted-by":"crossref","first-page":"112516","DOI":"10.18632\/oncotarget.22367","article-title":"Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: a comparative study between Texas and National SEER areas","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.clml.2023.04.004_bib0003","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14699","article-title":"Incidence and survival trends in mantle cell lymphoma","volume":"181","author":"Epperla","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.04.004_bib0004","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.04.004_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(00)00255-2","article-title":"Mantle-cell lymphoma","volume":"2","author":"Barista","year":"2001","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.04.004_bib0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/hupa.2002.30221","article-title":"From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades","volume":"33","author":"Swerdlow","year":"2002","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.clml.2023.04.004_bib0007","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/modpathol.2009.140","article-title":"Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms","volume":"23","author":"Chen","year":"2010","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.clml.2023.04.004_bib0008","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-016-0060-9","article-title":"SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma","volume":"4","author":"Narurkar","year":"2016","journal-title":"Biomark Res"},{"issue":"11","key":"10.1016\/j.clml.2023.04.004_bib0009","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2023.04.004_bib0010","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 rearrangements are the most frequent genetic events in cyclin D1\u2014mantle cell lymphoma","volume":"121","author":"Salaverria","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.04.004_bib0011","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1182\/blood-2007-10-118794","article-title":"Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas","volume":"111","author":"Wlodarska","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.04.004_bib0012","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.clml.2023.04.004_bib0013","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","article-title":"Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2023.04.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-019-0684-8","article-title":"Leukemic non-nodal mantle cell lymphoma: diagnosis and treatment","volume":"20","author":"Jain","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.04.004_bib0015","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc. Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.clml.2023.04.004_bib0016","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"issue":"5\u20136","key":"10.1016\/j.clml.2023.04.004_bib0017","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","article-title":"Genomic landscape and prognostic analysis of mantle cell lymphoma","volume":"25","author":"Yang","year":"2018","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"10.1016\/j.clml.2023.04.004_bib0018","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.04.004_bib0019","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2023.04.004_bib0020","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/cncr.31328","article-title":"Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy","volume":"124","author":"Greenwell","year":"2018","journal-title":"Cancer"},{"issue":"127","key":"10.1016\/j.clml.2023.04.004_bib0021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","article-title":"Implications of Genetic and Epigenetic Alterations of CDKN2A (p16INK4a) in Cancer","volume":"8","author":"Zhao","year":"2016","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.clml.2023.04.004_bib0022","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/cancers12082120","article-title":"Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy","volume":"12","author":"Malarikova","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.clml.2023.04.004_bib0023","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2141.2009.07739.x","article-title":"The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target","volume":"146","author":"Cheung","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.clml.2023.04.004_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0174809","article-title":"TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: evidence from a meta-analysis","volume":"12","author":"Xu","year":"2017","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.clml.2023.04.004_bib0025","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.04.004_bib0026","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.clml.2023.04.004_bib0027","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halld\u00f3rsd\u00f3ttir","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2023.04.004_bib0028","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/modpathol.2016.178","article-title":"P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC\/BCL2 expression in diffuse large B-cell lymphoma","volume":"30","author":"Wang","year":"2017","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.clml.2023.04.004_bib0029","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2023.04.004_bib0030","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2011-12-400580","article-title":"Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma","volume":"119","author":"Nygren","year":"2012","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:48Z","timestamp":1761871368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2152265023001337"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.04.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}